Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

AusCann Cannabis Stocks

AusCann Cannabis Stock (ACNNF)

AusCann is a pharmaceutical company focusing on pre-clinical drug candidate development and production. They focus on cannabinoid drug candidates and are located in Australia.

Is AusCann Cannabis Stock (ACNNF) a strong BUY and HOLD?

ACNNF Fundamental Analysis

Profile

HQ: Perth, Western Australia
Founded: 2013
Symbol: ACNNF (OTC), AC8 (ASX)

FocusStrong 

Producing and selling medical cannabis to patients in Australia, and later the world. They are focused on creating cannabis treatments for pain, plus other conditions.  This is a $9 billion market in Australia alone. Many investors know of them from their relationship (now closed) with Canopy Growth. 

Size: Neutral

Market Cap: $31.6 mil
Enterprise Value: $17.94 mil
Number of Employees: 32

Markets: Neutral

Primary: Initially Australia (and Tasmania), where medical MJ is legal, but adult use is not (nor expected soon). Also Chile, through a partnership

Secondary: MA, CT, PA, and CA in the near future, Canada

Subsidiaries, Interests:
DayaCann (Chile), Yarra Glen Vineyards Holdings, ACN 096 717 458 Pty Ltd, Australian Commercial Wines Pty Ltd.
 

Operations: Neutral

Cultivation: None
Current production: Drug development focusing on their first product, for chronic pain, a dry powder 50:50 ratio of THC:CBD in a hard shell capsule formulation.

Distribution: Initial sales of their capsules are currently being ordered.
Direct sales: Yes

Store networks: Has an agreement with the leading Australian pharmacy API to distribute medical cannabis through nationwide pharmacy networks

Integration/Diversification: 
Vertically integrated: Yes
Horizontally diversified: No

Financials: Weak

Revenue (2019): $671,000
Shares Outstanding (diluted): 317 million
Return on Equity: -18.55%

Management: Neutral

CEO: Nick Woolf
CFO: Quentin Megson
Director: Max Johnston
Director: Bruce McHarrie
Director: Krista Bates

Old CEO Ido Kanyon stepped down in May. Much of the Board also turned over this year. The end of their relationship with Canopy late last year also shifted the directors. There has been a LOT of turnover for AusCann.

Branding: Neutral

Most of their drugs cover anti-convulsion, anti-inflammatory, anti-nausea, glaucoma, pain management, and appetite stimulation areas. They have not branded any of their drug candidates yet as none are approved.

Valuation: Weak

Current share price: $0.095
Price to Sales: 13,190
52 week low/high: $0.067-$0.25
EV/Revenue: 5,600
Price/Book: 1.22

Financing: Strong

AusCann has no debt but is burning cash fast, typical of most pharma companies undergoing drug development. Clinical trials are expensive, and they have over $34 million to pay for the next few (company net assets were reported at $34.37 million). They reported $7 million in losses last fiscal year. 

 

ACNNF Technical Analysis

Should I buy AusCann Cannabis Stock?

Is AusCann Cannabis Stock (ACNNF) a Buy?

Follow Stephen Goldman as he investigates the differences between common momentum-based indicators such as the MACD and KST (Know Sure Thing) while learning how to spot opportunities to buy and sell AusCann.

Remember sound cannabis stock trading strategies include both Fundamental Analysis and Technical Analysis.

52 week Range -
/

Bottom Line: Is AusCann Cannabis Stock (ACNNF) a Buy?

Recommendation: Weak

Is AusCann Cannabis Stock (ACNNF) a Buy?

AusCann is often referred to as having the lead position in the Australian cannabis industry. They used to have Canopy Growth as 10% investors but now Canopy has been replaced by local Australian Merchant Capital.

From a licensing perspective, they are ahead of other competitors in Australia. They can produce, sell import, and export. They may have a strong position if they can deliver on production and distribution. It’s a big unknown.

The company has reported only $671k in revenue for the year ending Dec 2019. This revenue was not based on sales as none of their drug candidates are approved. The drug furthest along is their 1:1 THC: CBD capsule for chronic pain indications. This would be a large market to enter (Pain drugs) but they are still a way away from sales for this drug.

Its price to sales ratio is an astronomical 13,000 and they EV/Revenue is 5,600. We don’t typically see values this high in our analyses (remember lower is better here).

They do have a partnership with Tasmanian Alkaloids Pty Ltd. to distribute medical cannabis in Tasmania. TasAlk produces 40% of the world’s alkaloid raw material and a partnership with DayaCann, the only licensed medicinal cannabis grower in Chile. These deals extend their reach internationally.

For all the reasons above, we rate this stock as Weak. Perhaps in a few more years, their drugs will be closer to approvals and they’ll be closer to revenue. Until then, expect dilution if you’re a shareholder.

For all the reasons above, we rate this stock as Weak but check out our other featured companies for many other winners in the cannabis and hemp industry.

Symbol Name Last Price Change % Change

Charlotte’s Web Reports Q1-2021 Results

Market share leader in full spectrum cannabidiol (CBD) hemp extract wellness products, Charlotte’s Web, reports Q1-2021 results. Let's take a look at the highlights for this hemp stock. [stock_market_widget type="combo" symbol="CWBHF" template="tablechart"...

Trulieve Acquires Harvest in Largest US Cannabis Transaction

With this announcement, Trulieve Creates the Most Profitable Multi-State Operator in the World's Largest Cannabis Market TALLAHASSEE, Fla. and PHOENIX, May 10, 2021 /PRNewswire/ -- Trulieve Cannabis Corp. ("Trulieve" or the "Company") (CSE: TRUL) (OTC: TCNNF) and...

Can Hemp Become a Mainstream Component in the Automotive Industry?

The automotive industry has been researching how to introduce hemp and other fiber into their production process for close to eighty years. In 1941 Henry Ford built a prototype of a car made almost entirely of bio-plastic and was to be fueled by hemp ethanol. These...

4 Hot Hemp Stocks to Buy Now

As we enter the second quarter of 2021, investors are becoming more aware of the fact that the hemp industry is booming. It was valued at $5 billion last year and it is estimated to reach more than $24 billion by 2026. Cannabis and hemp stock investors understand the...

Is Microdosing Psychedelics Good for You?

If you have been following the trends lately, you might have noticed a considered increase in the number of people microdosing on psychedelics regularly. Several stories have come out about how Silicon Valley entrepreneurs microdose on psychedelics regularly and how...

Trulieve: When to Buy or Sell this Cannabis Stock

Fundamentally, Trulieve should be one of the best cannabis stocks to buy - but what does the technical analysis tell us? Let's dive into Trulieve and when to buy or sell this cannabis stock. Trulieve Cannabis (OTC: TCNNF) continues to grow steadily and now holds a 52%...

Cannin’s Top 5 Psychedelic Stocks for 2021

For several years, investors have been excited about the emergence and growth potential of cannabis stocks. What started as unabated enthusiasm for cannabis stocks has now calmed to strategic patience. Currently, many investors are waiting for the cannabis industry to...

How is Patagonia Creating a Domestic Supply Chain for Hemp Fiber?

The Hemp fiber industry continues to grow at an incredible rate. In fact, the fiber is one of the primary sources of fiber for large-scale manufacturing. This is because hemp fiber is both biodegradable and eco-friendly - its also more durable and versatile than...

ScottsMiracle-Gro Announces Record Second Quarter Results

The team at Cannin.com has a demonstrated track record of picking winning cannabis stocks and we've been long time fans of SMG. Today, ScottsMiracle-Gro announces record second quarter results as sales increased by 32% and is driven by strong demand in both major...

Biden Proposes Plan to Pay Hemp Farmers for Carbon

Farmers across America are well-positioned to benefit from President Biden as he proposes his plan to pay hemp farmers adopting carbon farming practices on their farms. This proposal comes as part of President Biden's commitment to half the United States’ greenhouse...